Ionis Pharmaceuticals IONS Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs?
- Ionis Pharmaceuticals (IONS) reported amortization expense related to capitalized debt issuance costs of $2.35M in Q1 2026.
- How has Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs increased by 43.1% year-over-year, from $1.64M to $2.35M.
- What is the long-term trend for Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's amortization expense related to capitalized debt issuance costs has grown at a 8.6% compound annual growth rate (CAGR), from $4.96M to $6.91M.